Tag: clinical trials

Chemotherapy Patient

Bills remove impediments to ill-advised state “right to try” laws, shield wrongdoers, and hide adverse events

Congressional bills will unleash state "right to try" laws, block terminally ill patients from redress for damages caused by negligent doctors and drug companies, and hide adverse drug events from the public.

/ March 2, 2017
Translational research and preclinical data

Donald Trump versus the FDA: Is the standard of evidence for drug approval actually too low rather than too high?

All of the candidates being considered by President Trump for FDA Commissioner believe that the FDA is too strict in its standards for approving new drugs. In a commentary in Nature last week, two bioethicists argued that, at least in terms of preclinical data, the standard of evidence is actually too low. Which is correct?

/ February 6, 2017
Not even the Bocca della Verità can tell if a Chinese medical study is fabricated.

Chinese BioMedical Research: Sturgeon’s Law In Action

A Chinese government investigation has found that 80%, yes eighty percent, of Chinese biomedical research is fabricated. I bet that is an underestimate for Traditional Chinese Pseudo-Medicine.

/ January 20, 2017
https://www.flickr.com/photos/euromagic/2351628831/

Peanut Allergy Prevention Advice Does a 180

New guidelines suggest that preventing peanut allergies may be as simple as giving peanut-containing food, beginning in infancy. How did old guidelines, which recommended avoidance, get it so wrong?

/ January 12, 2017
Martin Shkreli testifying

R&D and the High Cost of Drugs

Until a year ago very few people had ever heard of Martin Shkreli. In 2015 the then-32-year-old CEO of Turing Pharmaceuticals LLC became the poster boy for Big Pharma eXXXcesses when Turing acquired rights to Daraprim, an antiparasitic drug used widely to treat toxoplasmosis. The acquisition itself wasn’t particularly controversial. Raising the price of Daraprim from $13.50 per pill to $750 per...

/ October 15, 2016
The stem cell hard sell returns.

The stem cell hard sell, Stemedica edition

Stemedica Cell Technologies, a San Diego company that markets stem cell treatments for all manner of ailments, likes to represent itself as very much science-based. There are very good reasons to question that characterization, based on the histories of the people who run the company, as well as the company's behavior.

/ September 26, 2016
The moon

The Cancer Moonshot: Hype versus reality

The Cancer Moonshot has been promoted as a strategy to break the logjam that seems to be holding up new, much more effective treatments for cancer. The key word is "seems," because in reality the Cancer Moonshot is more hype than promise.

/ September 12, 2016
"This patient's qi isn't flowing the way it should. Consult Acupuncture, STAT!!"

On the pointlessness of acupuncture in the emergency room…or anywhere else

As incredible as it seems, advocates of "integrative medicine" are on the verge of creating a new specialty, emergency acupuncture. I wish I were joking, but I'm not.

/ July 25, 2016
Randomized controlled clinical trial

Whither the randomized controlled clinical trial?

With the rise of precision medicine and genomics, the conventional randomized clinical trial appears more and more outdated. Fortunately, clinical trials are evolving, but will it be enough to incorporate the numerous advances in "-omic" medicine in a rigorous scientific manner to benefit patients?

/ June 20, 2016

False balance about Stanislaw Burzynski and his disproven cancer therapy, courtesy of STAT News

One common theme that has been revisited time and time again on this blog since its very founding is the problem of how science and medicine are reported. For example, back when I first started blogging, years before I joined Science-Based Medicine in 2008, one thing that used to drive me absolutely nuts was the tendency of the press to include in...

/ June 5, 2016